Q1 2025 13F Holders as of 31 Mar 2025
-
Type / Class
-
Equity / Common Stock, $0.0001 par value per share
-
Shares outstanding
-
42,194,093
-
Number of holders
-
191
-
Total 13F shares, excl. options
-
43,564,795
-
Shares change
-
+3,098,029
-
Total reported value, excl. options
-
$2,238,109,644
-
Value change
-
+$155,550,097
-
Put/Call ratio
-
38%
-
Number of buys
-
98
-
Number of sells
-
-105
-
Price
-
$51.37
Significant Holders of Tarsus Pharmaceuticals, Inc. - Common Stock, $0.0001 par value per share (TARS) as of Q1 2025
233 filings reported holding TARS - Tarsus Pharmaceuticals, Inc. - Common Stock, $0.0001 par value per share as of Q1 2025.
Tarsus Pharmaceuticals, Inc. - Common Stock, $0.0001 par value per share (TARS) has 191 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 43,564,795 shares
.
Largest 10 shareholders include RTW INVESTMENTS, LP (3,316,032 shares), BlackRock, Inc. (3,153,728 shares), Paradigm Biocapital Advisors LP (2,610,197 shares), JENNISON ASSOCIATES LLC (2,492,640 shares), TANG CAPITAL MANAGEMENT LLC (2,454,797 shares), VANGUARD GROUP INC (2,226,595 shares), MORGAN STANLEY (2,012,777 shares), TORONTO DOMINION BANK (1,874,745 shares), Deep Track Capital, LP (1,484,266 shares), and Frazier Life Sciences Management, L.P. (1,397,527 shares).
This table shows the top 191 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.